ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019


Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday  December 9, 2019.  ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results. 

Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 1764134.  A webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit .

For further information, please contact:

Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
+41 22 308 6220 Office
+41 79 476 26 87 Mobile

Media Contact U.S.:
Marion Janic
RooneyPartners LLC
+1 212 223 4017 Office
+1 646 537 5649 Mobile

CEO Office Contact:
Shauna Dillon
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Scandinavian Tobacco Group A/S: Transaktioner i forbindelse med aktietilbagekøbsprogram28.9.2020 10:00:00 CESTpressemeddelelse

Selskabsmeddelelse Nr. 30/2020 København, 28. september 2020 Transaktioner i forbindelse med aktietilbagekøbsprogram Den 28. august 2020 informerede Scandinavian Tobacco Group A/S (“STG”) om iværksættelsen af et aktietilbagekøbsprogram til en samlet pris på op til DKK 300 millioner med det formål at justere selskabets kapitalstruktur og opfylde forpligtelserne i forhold til koncernens aktiebaserede incitamentsprogram. Aktietilbagekøbsprogrammet vil blive gennemført i overensstemmelse med EU-forordning nr. 596/2014 af 16. april 2014 (Markedsmisbrugsforordningen) og Kommissionens delegerede forordning (EU) 2016/1052, de såkaldte Safe Harbour-regler. Aktietilbagekøbsprogrammet slutter senest den 26. februar 2021. Følgende transaktioner er foretaget i perioden 21. september - 25. september 2020: Antal aktierGennemsnitlig købspris, DKKTransaktionsværdi, DKK Total, seneste opgørelse 393.367 38.572.530 21. september 2020 16.511 91.28 1.507.084 22. september 2020 19.632 92.19 1.809.878 23. sep

Scandinavian Tobacco Group A/S: Transactions in connection with share buy-back programme28.9.2020 10:00:00 CESTPress release

Company Announcement No. 30/2020 Copenhagen, 28 September 2020 Transactions in connection with share buy-back programme On 28 August 2020, Scandinavian Tobacco Group A/S (“STG”) announced that a share buy-back programme of an aggregated price of up to DKK 300 million was launched with the purpose to adjust the Company’s capital structure and meet obligations relating to the Group’s share-based incentive programme. The buy-back programme is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. The share buy-back programme will end no later than 26 February 2021. The following transactions have been executed from 21 September to 25 September 2020: Number of sharesAverage purchase price, DKKTransaction value, DKK Accumulated, last announcement 393,367 38,572,530 21 September 2020 16,511 91.28 1,507,084 22 Sept


Stockholm, Sweden, September 28, 2020 – Hoylu, a leader in visual collaboration solutions for distributed teams, announced today the immediate addition of two powerful new features to Hoylu workspaces for all users. Voting and Timer are available now to all registered users of Hoylu, and expand functionality for new and existing workspaces. Available as part of every workspace, users can now place votes using emojis, icons and symbols on notes and tasks. This functionality enhances project planning, retrospectives, brainstorming and task management by offering engaging user participation that can help guide workplace decisions. Voting objects are fully flexible and quickly tallies items for ease of use by project managers or workspace owners. The timer functionality allows synchronization of tasks and projects by allowing users to add a flexible timer to any workspace that counts down to a deadline for all users. Timers persist outside of active use, making it easy for short or long-te


Stockholm, Sverige, 28 september 2020 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, tillkännagav idag det omedelbara tillskottet av två kraftfulla nya funktioner i Hoylu-workspaces för alla användare. Voting (röstning) och Timer är tillgängliga nu för alla registrerade Hoylu-användare, och utökar därmed funktionaliteten för nya och befintliga arbetsytor. Tillgängliga som en del av varje arbetsyta, kan användare nu placera röster med emojis, ikoner och symboler på anteckningar och uppgifter. Denna funktionalitet förbättrar projektplanering, retrospektiv, brainstorming och uppgiftshantering genom att erbjuda engagerande användardeltagande som kan underlätta och ge vägledning i olika beslut på arbetsplatsen. Röstningsobjekten är fullt flexibla och objekten stämmer snabbt vilket förenklar användningen av funktionerna för projektledarna eller arbetsytornas ägare. Timerfunktionen tillåter synkronisering av uppgifter och projekt genom att användarna kan lägga till

Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer28.9.2020 07:15:00 CESTPress release

Basel, Switzerland, September 28, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 study, FIDES-03, with the FGFR inhibitor derazantinib. The multi-cohort study is evaluating derazantinib in patients with advanced gastric cancer with FGFR genetic aberrations. Derazantinib will be assessed as monotherapy and in combination with other cancer treatments, for instance with Roche’s PD-L1 checkpoint inhibitor, atezolizumab. Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab. Dr. Marc Engelhardt, Basilea’s Chief Medical Officer, said: “Our development strategy for derazantinib is focused on strengthening the clinical evidence on the differentiation versus other FGFR inhibitors. The unique kinase inhibition profile of derazantinib, results from preclinical studies and the safety and tolerability profile observed in clinical studies, provide a strong rationale for evaluating the drug candidate in patient